Brookline Capital Management Weighs in on MNPR Q1 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Stock analysts at Brookline Capital Management issued their Q1 2025 EPS estimates for Monopar Therapeutics in a research note issued to investors on Monday, January 6th. Brookline Capital Management analyst K. Dolliver forecasts that the company will post earnings of ($0.78) per share for the quarter. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. Brookline Capital Management also issued estimates for Monopar Therapeutics’ Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($1.27) EPS and FY2025 earnings at ($4.07) EPS.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09.

MNPR has been the subject of a number of other research reports. Rodman & Renshaw initiated coverage on shares of Monopar Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $50.00 price objective for the company. Piper Sandler initiated coverage on shares of Monopar Therapeutics in a report on Friday. They issued an “overweight” rating and a $72.00 price objective for the company. Finally, HC Wainwright lifted their price objective on shares of Monopar Therapeutics from $6.00 to $22.00 and gave the company a “buy” rating in a report on Monday, November 11th.

Monopar Therapeutics Stock Performance

Monopar Therapeutics stock opened at $25.35 on Thursday. The company’s 50 day simple moving average is $21.84 and its 200-day simple moving average is $10.70. The company has a market capitalization of $133.80 million, a price-to-earnings ratio of -12.87 and a beta of 1.23. Monopar Therapeutics has a 1 year low of $1.54 and a 1 year high of $38.50.

Insiders Place Their Bets

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan purchased 1,550 shares of Monopar Therapeutics stock in a transaction that occurred on Monday, October 28th. The stock was purchased at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the transaction, the chief financial officer now directly owns 1,550 shares in the company, valued at $25,187.50. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 34.90% of the stock is currently owned by company insiders.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.